Krystal Biotech Reports Third-Quarter 2026 Results
Krystal Biotech reported $127.3 million in global VYJUVEK revenue for the third quarter and $1.1 billion since launch.
Story updates
12:08:20 PM UTC
SquawkNews
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launchVYJUVEK pricing negotiations in Germany and Italy completedKB113 clinical data demonstrate regression in more than 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndromeStrong balance sheet, ending the q…
12:08:39 PM UTC
SquawkNews
Krystal Biotech authorized a share repurchase program of up to $400M, with repurchases expected opportunistically over the next two years. Third-quarter VYJUVEK revenue was $127.3M, up 30% year over year.Material DetailsContext by AI AnalystThis is a commercial-stage update, with VYJUVEK growth alo…
12:08:44 PM UTC
SquawkNews
*-- Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q3 Revenue $127.3M, vs.
12:15:41 PM UTC
SquawkNews
Krystal Biotech Q3 product revenue rises 30% on VYJUVEK demand Overview Biotech firm's Q3 product re